GLP-1 Research · Body Composition
At full therapeutic doses, published research shows that 25 to 40 percent of total weight lost on GLP-1 therapy can come from lean tissue rather than fat. A 2025 trial reported an average lean mass loss of approximately 1.9 pounds, representing roughly 25 percent of total weight lost. That figure is meaningful, but it is also highly modifiable. The difference between losing significant lean tissue and losing almost none comes down to three variables that are entirely within the patient's control.
Sources: 2025 PMC clinical trial data; Mass General Hospital nutritional guidance for GLP-1 patients; published resistance training literature.
Lean Mass Loss as Percentage of Total Weight Lost on GLP-1
Source: Aggregated from STEP and SURPASS subgroup analyses with lean mass preservation interventions.
GLP-1 receptor agonists suppress appetite without distinguishing between macronutrients, so total dietary intake decreases across the board. Lean mass loss follows when three conditions converge: protein falls below the threshold for muscle protein synthesis, resistance training stimulus is absent, and the caloric deficit is aggressive enough that fat stores cannot supply the shortfall alone. All three are most likely on full dose injectable protocols, where severe appetite suppression leads users to eat less of everything without realizing the protein gap.
| Factor | Full Dose Injectable GLP-1 | Microdose Protocol |
|---|---|---|
| Appetite suppression | Aggressive | Moderate |
| Typical caloric intake | Often 700–900 kcal/day | Moderate deficit maintained |
| Protein deficit risk | High without active tracking | Manageable with tracking |
| Lean mass loss risk | 25–40% of total weight lost | Substantially reduced |
| Training output sustainability | Often compromised by low intake | Generally maintained |
Comparison based on published observational data and mechanistic literature. Individual results vary. Not a clinical prediction.
Protein is the primary determinant of whether lean mass survives a caloric deficit. The evidence based target is 1.2 to 1.6 grams per kilogram of current body weight daily, distributed evenly across at least three meals of 25 to 40 grams each. Research from Mass General Hospital identifies this range as the minimum for lean mass preservation during active weight loss. The practical challenge is that GLP-1 suppresses appetite without signaling which macronutrient is missing, so deliberate protein tracking for the first six to eight weeks is the most reliable way to prevent the drift that leads to lean tissue loss.
Resistance training is the most effective non-dietary intervention for lean mass preservation during a caloric deficit. Mechanical tension on muscle fibers sends an anabolic signal that counteracts catabolic pressure from caloric restriction, communicating to the body that the tissue is load bearing and should not be used as fuel. Two to three sessions per week is the minimum effective dose, with compound movements including squats, deadlifts, rows, and presses generating the strongest stimulus. A 2025 PMC study confirmed that resistance training combined with GLP-1 therapy produced substantially better body composition outcomes than GLP-1 therapy alone.
Full dose injectable protocols can suppress appetite to the point where users inadvertently consume 700 to 900 calories per day. At that level of restriction, adequate protein and consistent training cannot fully protect lean mass because the deficit exceeds what fat stores alone can supply. Precision microdosing produces a more moderate appetite effect, creating a meaningful caloric deficit without triggering severe restriction. The body retains the metabolic space to preferentially oxidize fat rather than lean tissue.
Figure 1
Estimated lean mass loss as % of total weight lost — by intervention
Note: Estimates derived from published GLP-1 clinical trial data and resistance training literature. Values represent population level ranges. Individual results vary. Not a clinical prediction.
Creatine monohydrate has one of the strongest evidence bases in sports nutrition for lean mass preservation during caloric restriction. It increases phosphocreatine stores in muscle, enabling greater training intensity and output during sessions, which directly strengthens the anabolic stimulus on which lean mass preservation depends. The evidence based dose is 3 to 5 grams daily, no loading phase required. It is inexpensive, well tolerated, and carries a clean safety record spanning decades. For GLP-1 users focused on body composition, it is the most justified supplement addition beyond adequate dietary protein.
Scale weight combines fat mass, lean mass, water, and glycogen, so a two pound weekly loss could represent fat, lean tissue, or water weight — three very different outcomes. More informative approaches include quarterly DEXA scanning for gold standard body composition data, bioelectrical impedance for accessible trend monitoring under consistent conditions, waist circumference as a proxy for visceral fat, and sustained strength on primary lifts as the most immediate real time signal that lean mass is being preserved.
Illustrative template. Adjust session days to individual schedule. Physician monitored protocol — all dosing at clinician discretion.
The lean mass concern associated with GLP-1 therapy is primarily a full dose injectable concern. A 2026 PMC study examining lean tissue outcomes in GLP-1 and GIP receptor agonist users reported that lean mass preservation was achievable when dietary protein was adequate, and this is considerably easier to satisfy at the more moderate appetite suppression levels that microdosing produces. For users who prioritize body composition alongside the metabolic benefits of GLP-1 receptor activation, a microdosing approach paired with adequate protein and consistent resistance training provides a more favorable lean mass profile than full dose protocols. Individual results vary, and all protocols require physician evaluation and monitoring.
Estimated Protocol Lever Contribution to Lean Mass Preservation
Source: Estimated contributions based on published lean mass preservation literature; illustrative.
A 3 minute intake is all it takes. A physician reviews your information and identifies the protocol matched to your specific symptom profile.
See Our Protocols